| Researchers have identified a receptor protein known as CHRM1 as a key player in prostate cancer cells' resistance to docetaxel, a commonly used chemotherapy drug to treat advanced cancer that has spread beyond the prostate. | |
|
| This article from Merck outlines how nanofiber meshes are used as local drug delivery platforms. | |
|
| A 10-year follow up study of nearly 2,500 U.S. men who received prostate cancer treatment will help inform decision making in terms of treatments and side effects for a diverse population. | |
|
| Because low-risk prostate cancer is unlikely to spread or impact survival, experts and guidelines recommend active surveillance, which involves regular monitoring and thus avoid or delay treatment like surgery or radiation therapy and their life-changing complications. | |
|
| This study considers the perspectives of primary care physicians (PCPs) and urologists on what facilitates and what creates barriers to active surveillance (AS) care for men with low-risk prostate cancer. | |
|
| Rutgers researchers can predict which patients will benefit from a popular prostate cancer drug – and have devised a strategy that may make the treatment work longer. | |
|
| Non-cancerous cells called stromal cells, which are found in and around prostate tumors, may be useful in assessing these tumors' potential to spread, and may even be targets for future prostate cancer treatments, according to a study led by researchers at Weill Cornell Medicine. | |